The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Sigma Healthcare’s (SIG) Managing Director and Chief Executive Officer, Mark Hooper, has tendered his resignation from the role after over a decade
  • Mark Hooper was first appointed in August 2010 at what the company describes as “a tough time for Sigma”
  • In line with his contract, Hooper has provided six months’ notice, with his departure expected by the end of October 2021
  • The Sigma board will begin its search for a new Chief Executive Officer shortly
  • Sigma shares are down 2.17 per cent, trading at 67.5 cents

After almost eleven years, Mark Hooper has tendered his resignation from the role of Managing Director and Chief Executive Officer of Sigma Healthcare (SIG).

Mark Hooper was first appointed in August 2010, through which time he has led the company through a major restructure following divestment of the pharmaceutical division to Aspen Pharma in 2011 and the acquisitions of CHS, MPS and MIA businesses between 2014 and 2018.

“Our transformation has progressed to plan and has returned Sigma to a position of strength, which creates the ideal opportunity to hand over the leadership to a new CEO,” said Mark Hooper.

“The business is now in great shape, the financial performance is strong, and we have built a platform for sustainable growth over the next few years.”

Hooper also held the role of Chair of the National Pharmaceutical Services Association (NPSA) from October 2015 to August 2020, and guided the company through its imminent implementation of a new enterprise resource planning system.

“Mark became CEO at a tough time for Sigma and put it on a pathway for a stronger future,” said Sigma Chairman Ray Gunston.

“He then undertook the biggest transformation in the company’s history and has set Sigma up for strong earnings growth. I personally, and all of us at Sigma, are very grateful for Mark’s hard work, vision and support over more than 10 years.”

In line with his contract, Hooper has provided six months’ notice, with his departure expected by the end of October 2021.

The Sigma board will begin its search for a new Chief Executive Officer shortly, both internally and externally.

Sigma shares are down 2.17 per cent, trading at 67.5 cents at 12:25 pm AEST. 

SIG by the numbers
More From The Market Online

This stock provides Oz’s only HIV self-test kit – and it’s bullish on the budget

Atomo Diagnostics is the only company in Australia that provides TGA-approved HIV self-test kits. It says…

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial…
The Market Online Video

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug…

Optiscan agreement with Mayo Clinic aims to expedite robotic surgery

Optiscan Imaging is parterning with Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system